{"id":"zebutinib-br-or-zebutinib-fcr","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Zebutinib covalently binds to BTK, a key enzyme in B-cell receptor signaling, thereby inhibiting downstream signaling pathways that promote malignant B-cell survival and proliferation. The drug is being evaluated in combination with chemotherapy regimens (BR: bendamustine and rituximab; FCR: fludarabine, cyclophosphamide, and rituximab) for chronic lymphocytic leukemia and other B-cell lymphomas.","oneSentence":"Zebutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell proliferation and survival in hematologic malignancies.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:41:21.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic lymphocytic leukemia (in combination with BR or FCR chemotherapy)"}]},"trialDetails":[{"nctId":"NCT04980859","phase":"PHASE3","title":"Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-09-01","conditions":"Chronic Lymphocytic Leukemia","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Zebutinib&BR or Zebutinib&FCR","genericName":"Zebutinib&BR or Zebutinib&FCR","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zebutinib is a Bruton's tyrosine kinase (BTK) inhibitor that blocks BTK signaling to suppress B-cell proliferation and survival in hematologic malignancies. Used for Chronic lymphocytic leukemia (in combination with BR or FCR chemotherapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}